John L. Stauffer

3.6k total citations · 1 hit paper
55 papers, 2.6k citations indexed

About

John L. Stauffer is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Epidemiology. According to data from OpenAlex, John L. Stauffer has authored 55 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Pulmonary and Respiratory Medicine, 17 papers in Physiology and 10 papers in Epidemiology. Recurrent topics in John L. Stauffer's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (26 papers), Respiratory and Cough-Related Research (11 papers) and Asthma and respiratory diseases (8 papers). John L. Stauffer is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (26 papers), Respiratory and Cough-Related Research (11 papers) and Asthma and respiratory diseases (8 papers). John L. Stauffer collaborates with scholars based in United States, Italy and Switzerland. John L. Stauffer's co-authors include Thomas L. Petty, Steven D. Nathan, Carlo Albera, Klaus-Uwe Kirchgaessler, Lisa Lancaster, Sandralee Blosser, João A. de Andrade, Marlies Wijsenbeek, Willis Chou and Ulrich Costabel and has published in prestigious journals such as JAMA, Hepatology and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

John L. Stauffer

53 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Complications and consequences of endotracheal intubation and tracheotomy

1981 878 citations John L. Stauffer, Thomas L. Petty et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John L. Stauffer United States	20	1.9k	707	693	594	190	55	2.6k
Leland L. Fan United States	33	2.6k 1.3×	175 0.2×	220 0.3×	1.2k 2.0×	497 2.6×	73	3.4k
Prashant N. Chhajed Switzerland	32	2.1k 1.1×	422 0.6×	358 0.5×	1.3k 2.3×	421 2.2×	113	3.0k
Thomas M. Berger Switzerland	24	620 0.3×	98 0.1×	302 0.4×	444 0.7×	236 1.2×	84	2.0k
Rosanna Vaschetto Italy	28	1.4k 0.7×	373 0.5×	131 0.2×	212 0.4×	191 1.0×	88	2.4k
Omar A. Minai United States	34	2.8k 1.4×	57 0.1×	583 0.8×	607 1.0×	457 2.4×	101	3.5k
Horng-Chyuan Lin Taiwan	24	602 0.3×	347 0.5×	305 0.4×	291 0.5×	349 1.8×	58	2.1k
Teresa Yae Takagaki Brazil	17	2.9k 1.5×	318 0.4×	76 0.1×	350 0.6×	560 2.9×	64	3.6k
John A. Dumot United States	37	1.7k 0.9×	1.0k 1.5×	121 0.2×	2.9k 4.8×	295 1.6×	130	4.0k
Luc Delaunois Belgium	20	1.1k 0.5×	48 0.1×	420 0.6×	195 0.3×	187 1.0×	69	1.7k
Wen‐Jue Soong Taiwan	20	624 0.3×	202 0.3×	94 0.1×	321 0.5×	232 1.2×	100	1.1k

Countries citing papers authored by John L. Stauffer

Since Specialization

Citations

This map shows the geographic impact of John L. Stauffer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John L. Stauffer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John L. Stauffer more than expected).

Fields of papers citing papers by John L. Stauffer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John L. Stauffer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John L. Stauffer. The network helps show where John L. Stauffer may publish in the future.

Co-authorship network of co-authors of John L. Stauffer

This figure shows the co-authorship network connecting the top 25 collaborators of John L. Stauffer. A scholar is included among the top collaborators of John L. Stauffer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John L. Stauffer. John L. Stauffer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Holtze, Colin, Elizabeth Freiheit, Susan L. Limb, et al.. (2020). Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry. Respiratory Research. 21(1). 48–48. 30 indexed citations

Kaner, Robert J., Ednan K. Bajwa, Moustapha El-Amine, et al.. (2019). Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies. American Journal of Respiratory and Critical Care Medicine. 200(2). 133–139. 7 indexed citations

Glassberg, Marilyn K., Steven D. Nathan, Chin‐Yu Lin, et al.. (2019). Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. Advances in Therapy. 36(10). 2910–2926. 14 indexed citations

Nathan, Steven D., Ulrich Costabel, Carlo Albera, et al.. (2018). EFFECT OF PIRFENIDONE ON EXERCISE CAPACITY AND DYSPNEA IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) AND MORE ADVANCED LUNG FUNCTION IMPAIRMENT. CHEST Journal. 154(4). 432A–433A. 1 indexed citations

Cleemput, Johan Van, Andrea Sonaglioni, Wim Wuyts, et al.. (2018). Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management. Advances in Therapy. 36(2). 298–317. 19 indexed citations

Ley, Brett, Jeffrey J. Swigris, John L. Stauffer, et al.. (2017). Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 196(6). 756–761. 131 indexed citations

Lancaster, Lisa, João A. de Andrade, Joseph D. Zibrak, et al.. (2017). Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. European Respiratory Review. 26(146). 170057–170057. 210 indexed citations

Djukanović, Ratko, Susan J. Wilson, Wendy C. Moore, et al.. (2010). Montelukast added to fluticasone propionate does not alter inflammation or outcomes. Respiratory Medicine. 104(10). 1425–1435. 8 indexed citations

Stauffer, John L., Steven W. Yancey, Leslie Baitinger, Barbara A. Prillaman, & Paul Dorinsky. (2006). Measuring Airway Hyperresponsiveness: Does it Add to Routine Measures of Clinical Efficacy in Guiding Asthma Therapy?. Journal of Allergy and Clinical Immunology. 117(2). S280–S280.

10.

Jarjour, Nizar N., Susan J. Wilson, Steven M. Koenig, et al.. (2006). Control of airway inflammation maintained at a lower steroid dose with 100/50 μg of fluticasone propionate/salmeterol. Journal of Allergy and Clinical Immunology. 118(1). 44–52. 28 indexed citations

11.

Dorinsky, Paul, Susan J. Wilson, Steve Yancey, et al.. (2005). CONTROL OF AIRWAY INFLAMMATION IS ACHIEVED IN ASTHMA PATIENTS WITH FLUTICASONE PROPIONATE ALONE: ADDING MONTELUKAST PROVIDES NO ADDITIONAL CONTROL OF AIRWAY INFLAMMATION. CHEST Journal. 128(4). 164S–164S. 1 indexed citations

12.

Nathan, Robert A., Steven W. Yancey, Barbara A. Prillaman, et al.. (2005). Fluticasone Propionate Nasal Spray Is Superior to Montelukast for Allergic Rhinitis While Neither Affects Overall Asthma Control. CHEST Journal. 128(4). 1910–1920. 32 indexed citations

13.

House, Karen, et al.. (2004). The Safety of Fluticasone propionate/Salmeterol Diskus® in Pediatric Patients Ages 4 –11 with Asthma. CHEST Journal. 126(4). 911S–911S. 8 indexed citations

14.

Hopper, Kenneth D., Kevin Gleeson, John L. Stauffer, et al.. (2001). Transbronchial Biopsy with Virtual CT Bronchoscopy and Nodal Highlighting. Radiology. 221(2). 531–536. 34 indexed citations

15.

Demers, Laurence M., L. Gaydos, John L. Stauffer, & Douglas C. Kuhn. (1996). Bacterial Endotoxin Primes the Human Alveolar Macrophage for Subsequent Stimulation by Silica but Silica Does Not Prime for Stimulation by Bacterial Endotoxin. Applied Occupational and Environmental Hygiene. 11(7). 909–913. 1 indexed citations

16.

Stauffer, John L., et al.. (1995). Inflammatory and fibrotic mediator release by alveolar macrophages from coal miners. Journal of Toxicology and Environmental Health. 46(1). 9–21. 5 indexed citations

17.

Stauffer, John L., et al.. (1993). Survival Following Mechanical Ventilation for Acute Respiratory Failure in Adult Men. CHEST Journal. 104(4). 1222–1229. 94 indexed citations

18.

Stauffer, John L., Edward O. Bixler, Francis E. Sharkey, et al.. (1989). Morphology of the Uvula in Obstructive Sleep Apnea. American Review of Respiratory Disease. 140(3). 724–728. 141 indexed citations

19.

Stauffer, John L. & Thomas L. Petty. (1978). Cleft Tongue and Ulceration of Hard Palate. CHEST Journal. 74(3). 317–318. 7 indexed citations

20.

Stauffer, John L.. (1973). Drug-Induced Lung Disease: The Price of Progress. PubMed Central. 119(4). 48. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact